Showing 1851-1860 of 3038 results for "".
- Eyevance’s Natacyn Now Available for Next-Day Deliveryhttps://modernod.com/news/eyevances-natacyn-now-available-next-day/2478883/Eyevance Pharmaceuticals announced that its anti-fungal ophthalmic medication, Natacyn (natamycin ophthalmic suspension 5%), is now available for next-day delivery. Natacyn, which Eyevance acquired from Novartis in 2019, is indicated for the treatment of fungal blepharitis, conjunctivitis,
- New World Medical’s Next-Generation KDB GLIDE Now Commercially Availablehttps://modernod.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/New World Medical announced the launch of the KDB GLIDE device for advanced excisional goniotomy treatment of glaucoma. The KDB GLIDE, which was registered with the FDA in October 2020, is now commercially available to ophthalmic surgeons across the US looking for refined, precise performance dur
- Lumibird Medical Creates Three Nordics Subsidiarieshttps://modernod.com/news/lumibird-medical-creates-three-nordics-subsidiaries/2478848/The Lumibird Medical Group announced the creation of Lumibird Medical Nordics AB in Sweden, Lumibird Medical Nordics OY in Finland, and Lumibird Medical Nordics AS in Norway. The creation of these three subsidi
- GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primateshttps://modernod.com/news/gensight-biologics-announces-the-publication-in-communications-biology-of-the-proof-of-concept-for-gs030-drug-product-in-none28091human-primates/2478834/GenSight Biologics announced that the journal Communications Biology has published results from the study of GS030-Drug Product (GS030-DP) in non-human primates (NHP). The paper,* published in the January issue under the title “Optogenetic therapy: high spatiotemporal resolution and
- Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane/2478770/Bausch + Lomb and Novaliq announced the first of two phase 3 studies evaluating NOV03 as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) has been completely enrolled w
- Notal Vision Launches First US Home OCT Longitudinal Study with Patient Self-Operated Devicehttps://modernod.com/news/notal-vision-launches-first-us-home-oct-longitudinal-study-with-patient-self-operated-device/2478748/Notal Vision announced that it has initiated the first US-based study using its investigational home-based optical coherence tomography (OCT) platform. The study will evaluate the ability of subjects with wet age-rela
- Prevent Blindness Issues Call for Nominations for Two Awardshttps://modernod.com/news/prevent-blindness-issues-call-for-nominations-for-two-awards/2478723/Prevent Blindness has issued the call for nominations for the “
- Physicians React: Doctors Worry About Patients Reading Their Clinical Noteshttps://modernod.com/news/physicians-react-doctors-worry-about-patients-reading-their-clinical-notes/2478707/Patients will soon be able to read the notes that physicians make during an episode of care, as well as information about diagnostic testing and imaging results, tests for sexually transmitted diseases, fetal ultrasounds, and cancer biopsies. This open access is raising concerns among physicians,
- Norlase Announce the Addition of Distributor Partnershipshttps://modernod.com/news/norlase-announce-the-addition-of-distributor-partnerships/2478690/Norlase announced the addition of distributor partnerships in Eastern Europe, Middle East, Oceania and Southeast Asia. “Following our recent expansion into the broader European countries, we are thrilled to establish distributor relationships in these key markets,” Oliver Hvidt, CEO and Pr
- Novartis Reports Positive Topline Results From Second Phase 3 Trial of Beovu in Patients With DMEhttps://modernod.com/news/novartis-reports-positive-topline-results-from-second-phase-3-trial-of-beovu-in-patients-with-dme/2478658/Novartis announced positive findings from the first interpretable results of the phase 3 KESTREL study, assessing the efficacy and safety of Beovu (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME). Following KITE, KESTREL is the second pivotal phase 3 study of Beovu in DME. The